Pierre Gravier serves as the Chief Financial Officer at PTC Therapeutics Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines for patients with rare disorders. In his role as CFO, Gravier is responsible for overseeing the financial operations and strategy of the company, ensuring its fiscal health and supporting its growth objectives. His leadership is crucial in navigating the complex financial landscape of the biopharmaceutical industry, where he manages budgeting, financial planning, and investor relations. Before joining PTC Therapeutics, Gravier held several high-profile positions in the finance sector, demonstrating a robust professional background that spans over two decades. He previously served as the CFO at Spark Therapeutics, where he played a pivotal role in the company's financial strategy and its eventual acquisition by Roche. His tenure at Spark was marked by significant achievements, including the successful launch of Luxturna, the first gene therapy for an inherited retinal disease. Gravier's expertise in financial management and strategic planning has been instrumental in driving growth and innovation in the companies he has served. Gravier's career also includes notable stints at major corporations such as Pfizer and Wyeth, where he honed his skills in corporate finance and business development. His educational background includes a Master of Business Administration from the University of Chicago Booth School of Business and a Bachelor of Science in Finance from the University of Illinois. At PTC Therapeutics, Gravier continues to leverage his extensive experience and strategic acumen to steer the company towards sustainable growth and success in the competitive biopharmaceutical market.